Health Official's Stock in Menopause Platform Raises Conflict of Interest Concerns Over Policy Shift

Alicia Jackson, the director of the Advanced Research Projects Agency for Health (ARPA-H), found herself at the center of a controversy after she praised a policy change that removed "black box" warnings from hormone replacement therapies. The decision, announced by the Department of Health and Human Services in November 2023, aimed to reverse nearly two decades of stigma surrounding these treatments for menopause symptoms.

Jackson's endorsement came during a press conference where she emphasized the benefits of hormone therapy, stating it could add up to ten healthy years to women's lives. However, ProPublica reports reveal that Jackson retained significant financial interests in Evernow, an online platform she founded and formerly led, which connects women with medical experts specializing in menopause care.

Jackson kept at least $115,000 worth of stock and undisclosed stock options from Evernow when she transitioned to her current role. This retention raises questions about potential conflicts of interest given that the removal of black box warnings could benefit companies like Evernow by increasing patient access to hormone replacement therapies.

Ethics experts have expressed alarm over Jackson's public endorsement of the policy change, noting that federal law prohibits government employees from participating in matters that could influence their personal finances. Virginia Canter, a former ethics lawyer for multiple administrations, stated that Jackson’s actions put her within the zone of potential legal violations due to her financial ties to Evernow.

Following the announcement, Evernow launched a nationwide expansion initiative, further fueling suspicions about the timing and implications of Jackson's involvement in the policy shift. ProPublica's investigation also revealed that Jackson has not yet certified her financial disclosure forms as required by federal law, leading some experts to suggest an internal review or even potential legal action.

In response to mounting questions and concerns, HHS placed Jackson on administrative leave last week without providing specific reasons for the decision. The agency stated it would assess the facts before determining any change in her status, emphasizing its commitment to compliance with ethics laws, regulations, and policies.

Despite requests from ProPublica and Bloomberg Law, HHS has remained tight-lipped about the specifics of Jackson's leave or whether an investigation is underway by the inspector general. The controversy highlights ongoing concerns about transparency and accountability within federal health agencies as they navigate complex ethical landscapes in policy-making.